<html>
	<head>
		<title>smithkline <skb>, boehringer finalize pact</title>
		<meta name="keywords" content="places usa">
</head>
<body>
	<h3>smithkline beckman corp said it and <boehringer mannheim gmbh> signed a final agreement to develop and market new cardiovascular medicines discovered by boehringer.     under the agreement, smithkline said, it will have responsibility for developing the products in the u.s. both partners will market the products in the u.s. and abroad.     initially, smithkline said, the companies will concentrate on the clinical development and marketing of carvedilol which is a compound to treat mild to moderate hypertension and angina.         an application for marketing approval of carvedilol was submitted in west germany last december, smithkline said. applications expected in other european markets this year and submission to the u.s. food and drug administration is projected for 1990.     it said work also underway on thromboxane receptor antagonists, compounds which could be useful in accelerating disolution of blood clots and preventing blod clots from occuring in a heart attack as well as in other arterial diseases. the company said two of these compounds are in clinical evaluation in europe and the u.s.  reuter &#3;</h3>
</body>
</html>